Prereferral rectal artesunate for treatment of severe childhood malaria

A cost-effectiveness analysis

Yeim Tozan, Eili Klein, Sarah Darley, Rajashree Panicker, Ramanan Laxminarayan, Joel G. Breman

Research output: Contribution to journalArticle

Abstract

Severely ill patients with malaria with vomiting, prostration, and altered consciousness cannot be treated orally and need injections. In rural areas, access to health facilities that provide parenteral antimalarial treatment is poor. Safe and effective treatment of most severe malaria cases is delayed or not achieved. Rectal artesunate interrupts disease progression by rapidly reducing parasite density, but should be followed by further antimalarial treatment. We estimated the cost-effectiveness of community-based prereferral artesunate treatment of children suspected to have severe malaria in areas with poor access to formal health care. We assessed the cost-effectiveness (in international dollars) of the intervention from the provider perspective. We studied a cohort of 1000 newborn babies until 5 years of age. The analysis assessed how the cost-effectiveness results changed with low (25), moderate (50), high (75), and full (100) referral compliance and intervention uptake. At low intervention uptake and referral compliance (25), the intervention was estimated to avert 19 disability-adjusted life-years (DALYs; 95 CI 16-21) and to cost I$1173 (95 CI 1050-1297) per DALY averted. Under the full uptake and compliance scenario (100), the intervention could avert 967 DALYs (884-1050) at a cost of I$77 (73-81) per DALY averted. Prereferral artesunate treatment is a cost-effective, life-saving intervention, which can substantially improve the management of severe childhood malaria in rural African settings in which programmes for community health workers are in place. The Disease Control Priorities Project; Fogarty International Center; US National Institutes of Health; and the Peter Paul Career Development Professorship, Boston University.

Original languageEnglish (US)
Pages (from-to)1910-1915
Number of pages6
JournalThe Lancet
Volume376
Issue number9756
DOIs
StatePublished - Dec 4 2010
Externally publishedYes

Fingerprint

Malaria
Cost-Benefit Analysis
Compliance
Antimalarials
Costs and Cost Analysis
Referral and Consultation
Therapeutics
Health Services Accessibility
Quality-Adjusted Life Years
Health Facilities
National Institutes of Health (U.S.)
Consciousness
Vomiting
Disease Progression
Parasites
artesunate
Newborn Infant
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prereferral rectal artesunate for treatment of severe childhood malaria : A cost-effectiveness analysis. / Tozan, Yeim; Klein, Eili; Darley, Sarah; Panicker, Rajashree; Laxminarayan, Ramanan; Breman, Joel G.

In: The Lancet, Vol. 376, No. 9756, 04.12.2010, p. 1910-1915.

Research output: Contribution to journalArticle

Tozan, Yeim ; Klein, Eili ; Darley, Sarah ; Panicker, Rajashree ; Laxminarayan, Ramanan ; Breman, Joel G. / Prereferral rectal artesunate for treatment of severe childhood malaria : A cost-effectiveness analysis. In: The Lancet. 2010 ; Vol. 376, No. 9756. pp. 1910-1915.
@article{4afd0d8eecc442a2a6eb5d4f7c2cca2b,
title = "Prereferral rectal artesunate for treatment of severe childhood malaria: A cost-effectiveness analysis",
abstract = "Severely ill patients with malaria with vomiting, prostration, and altered consciousness cannot be treated orally and need injections. In rural areas, access to health facilities that provide parenteral antimalarial treatment is poor. Safe and effective treatment of most severe malaria cases is delayed or not achieved. Rectal artesunate interrupts disease progression by rapidly reducing parasite density, but should be followed by further antimalarial treatment. We estimated the cost-effectiveness of community-based prereferral artesunate treatment of children suspected to have severe malaria in areas with poor access to formal health care. We assessed the cost-effectiveness (in international dollars) of the intervention from the provider perspective. We studied a cohort of 1000 newborn babies until 5 years of age. The analysis assessed how the cost-effectiveness results changed with low (25), moderate (50), high (75), and full (100) referral compliance and intervention uptake. At low intervention uptake and referral compliance (25), the intervention was estimated to avert 19 disability-adjusted life-years (DALYs; 95 CI 16-21) and to cost I$1173 (95 CI 1050-1297) per DALY averted. Under the full uptake and compliance scenario (100), the intervention could avert 967 DALYs (884-1050) at a cost of I$77 (73-81) per DALY averted. Prereferral artesunate treatment is a cost-effective, life-saving intervention, which can substantially improve the management of severe childhood malaria in rural African settings in which programmes for community health workers are in place. The Disease Control Priorities Project; Fogarty International Center; US National Institutes of Health; and the Peter Paul Career Development Professorship, Boston University.",
author = "Yeim Tozan and Eili Klein and Sarah Darley and Rajashree Panicker and Ramanan Laxminarayan and Breman, {Joel G.}",
year = "2010",
month = "12",
day = "4",
doi = "10.1016/S0140-6736(10)61460-2",
language = "English (US)",
volume = "376",
pages = "1910--1915",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9756",

}

TY - JOUR

T1 - Prereferral rectal artesunate for treatment of severe childhood malaria

T2 - A cost-effectiveness analysis

AU - Tozan, Yeim

AU - Klein, Eili

AU - Darley, Sarah

AU - Panicker, Rajashree

AU - Laxminarayan, Ramanan

AU - Breman, Joel G.

PY - 2010/12/4

Y1 - 2010/12/4

N2 - Severely ill patients with malaria with vomiting, prostration, and altered consciousness cannot be treated orally and need injections. In rural areas, access to health facilities that provide parenteral antimalarial treatment is poor. Safe and effective treatment of most severe malaria cases is delayed or not achieved. Rectal artesunate interrupts disease progression by rapidly reducing parasite density, but should be followed by further antimalarial treatment. We estimated the cost-effectiveness of community-based prereferral artesunate treatment of children suspected to have severe malaria in areas with poor access to formal health care. We assessed the cost-effectiveness (in international dollars) of the intervention from the provider perspective. We studied a cohort of 1000 newborn babies until 5 years of age. The analysis assessed how the cost-effectiveness results changed with low (25), moderate (50), high (75), and full (100) referral compliance and intervention uptake. At low intervention uptake and referral compliance (25), the intervention was estimated to avert 19 disability-adjusted life-years (DALYs; 95 CI 16-21) and to cost I$1173 (95 CI 1050-1297) per DALY averted. Under the full uptake and compliance scenario (100), the intervention could avert 967 DALYs (884-1050) at a cost of I$77 (73-81) per DALY averted. Prereferral artesunate treatment is a cost-effective, life-saving intervention, which can substantially improve the management of severe childhood malaria in rural African settings in which programmes for community health workers are in place. The Disease Control Priorities Project; Fogarty International Center; US National Institutes of Health; and the Peter Paul Career Development Professorship, Boston University.

AB - Severely ill patients with malaria with vomiting, prostration, and altered consciousness cannot be treated orally and need injections. In rural areas, access to health facilities that provide parenteral antimalarial treatment is poor. Safe and effective treatment of most severe malaria cases is delayed or not achieved. Rectal artesunate interrupts disease progression by rapidly reducing parasite density, but should be followed by further antimalarial treatment. We estimated the cost-effectiveness of community-based prereferral artesunate treatment of children suspected to have severe malaria in areas with poor access to formal health care. We assessed the cost-effectiveness (in international dollars) of the intervention from the provider perspective. We studied a cohort of 1000 newborn babies until 5 years of age. The analysis assessed how the cost-effectiveness results changed with low (25), moderate (50), high (75), and full (100) referral compliance and intervention uptake. At low intervention uptake and referral compliance (25), the intervention was estimated to avert 19 disability-adjusted life-years (DALYs; 95 CI 16-21) and to cost I$1173 (95 CI 1050-1297) per DALY averted. Under the full uptake and compliance scenario (100), the intervention could avert 967 DALYs (884-1050) at a cost of I$77 (73-81) per DALY averted. Prereferral artesunate treatment is a cost-effective, life-saving intervention, which can substantially improve the management of severe childhood malaria in rural African settings in which programmes for community health workers are in place. The Disease Control Priorities Project; Fogarty International Center; US National Institutes of Health; and the Peter Paul Career Development Professorship, Boston University.

UR - http://www.scopus.com/inward/record.url?scp=78649821541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649821541&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)61460-2

DO - 10.1016/S0140-6736(10)61460-2

M3 - Article

VL - 376

SP - 1910

EP - 1915

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9756

ER -